What is Anika Therapeutics's free cash flow yield?

Anika Therapeutics (ANIK) reported free cash flow yield of 0.5% in Q1 2026.

What does free cash flow yield mean?

Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.

Anika Therapeutics ANIK Free cash flow yield

Free cash flow yield at other companies

StrykerSYK

3.6%+1.1pp

VericelVCEL

2.9%—

Zimmer Biomet HoldingsZBH

8.2%+1.8pp

Pacira BioSciences, Inc.PCRX

14.5%+0.6pp

BioventusBVS

16.4%+12.4pp

Xtant Medical HoldingsXTNT

9.9%+6.2pp

Other financials

Income statement

See full

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

See full

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

See full

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

See full

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

See full

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

See full

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Calculated from Anika Therapeutics’s reported figures.

free cash flow/market cap=0.5%

Based on trailing twelve months.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Anika Therapeutics's free cash flow yield?: Anika Therapeutics (ANIK) reported free cash flow yield of 0.5% in Q1 2026.
What does free cash flow yield mean?: Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.